{"nctId":"NCT01513473","briefTitle":"A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus","startDateStruct":{"date":"2012-01-16","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"count":350,"armGroups":[{"label":"Insulin Degludec + Insulin Aspart","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]},{"label":"Insulin Detemir +Insulin Aspart","type":"EXPERIMENTAL","interventionNames":["Drug: insulin detemir","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin detemir","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent, and child assent as age-appropriate, obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject). The parents or legal representative of the child must sign and date the Informed Consent Form according to local requirements. The child, if possible, parents or legal representative of the child must sign and date the Child Assent Form according to local requirements\n* Male or female diagnosed with type 1 diabetes mellitus (T1DM) (based on clinical judgement and supported by laboratory analysis as per local guidelines)\n* Ongoing daily treatment with insulin (any regimen) for at least 3 months prior to Visit 1 (screening). No OADs (oral anti-diabetic drugs) are allowed\n* HbA1c (glycosylated haemoglobin) maximum 11%\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to trial product(s) or related products\n* Previous participation in this trial. Participation is defined as randomisation\n* Girls who are pregnant, breastfeeding or intend to become pregnant\n* Girls who have had menarche and are not using adequate contraceptive measures according to local requirements\n* Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the Investigator (trial physician)\n* More than 1 diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1\n* Significant concomitant disease, except for conditions associated with type 1 diabetes mellitus, which in the Investigator's opinion could interfere with the trial\n* The receipt of any investigational drug within 1 month prior to Visit 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)","description":"Change from baseline in HbA1c (%) after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.95"},{"groupId":"OG001","value":"-0.31","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (%) at 52 Weeks (Analysed by Central Laboratory)","description":"Change from baseline in HbA1c (%) after 52 weeks of treatments.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"1.07"},{"groupId":"OG001","value":"-0.22","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Blood Glucose (FPG) at 26 Weeks (Analysed by Central Laboratory)","description":"Change from baseline in FPG after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":"5.99"},{"groupId":"OG001","value":"0.50","spread":"8.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Blood Glucose (FPG) at 52 Weeks (Analysed by Central Laboratory)","description":"Change from baseline in FPG after 52 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.29","spread":"6.53"},{"groupId":"OG001","value":"1.10","spread":"8.24"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (TEAEs)","description":"TEAE is defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"810","spread":null},{"groupId":"OG001","value":"761","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1462","spread":null},{"groupId":"OG001","value":"1266","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hypoglycaemic Episodes","description":"Number of hypoglycaemic episodes (severe episodes or episodes with plasma glucose (PG) below or equal to 3.9 mmol/L (70 mg/dL) with or without symptoms of hypoglycaemia) during the trial; nocturnal \\[11 p.m. - 7 a.m./23:00 - 07:00\\] and over the entire day (24 hours)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11712","spread":null},{"groupId":"OG001","value":"10991","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1261","spread":null},{"groupId":"OG001","value":"1458","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21560","spread":null},{"groupId":"OG001","value":"18373","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2336","spread":null},{"groupId":"OG001","value":"2586","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Self-measured Hyperglycaemia (Episodes of PG Above 11.1 mmol/L (200 mg/dL))","description":"Episodes of PG \\>11.1mmol/L (200mg/dL)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31264","spread":null},{"groupId":"OG001","value":"31173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58679","spread":null},{"groupId":"OG001","value":"52831","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Episodes With Self Monitored Blood Ketones Above 1.5 mmol (Capillary Blood Ketone Measurement to be Performed if Self-measured Plasma Glucose (SMPG) Exceeds 14.0 mmol/l (250 mg/dL))","description":"Blood ketones \\> 1.5mmol/L (Capillary blood ketone measurement to be performed if SMPG exceeds 14.0mmol/L (250mg/dL) )after 26 and 52 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"161","spread":null}]}]}]},{"type":"SECONDARY","title":"Steady-state Plasma Concentrations of Insulin Degludec and Insulin Detemir on Three Different Visits (Three Different Weeks) During the First 26 Weeks of Treatment","description":"Steady state plasma concentrations of insulin degludec and insulin detemir on three different visits (three different weeks) during the trial.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4540.4","spread":"3999.0"},{"groupId":"OG001","value":"3972.2","spread":"6721.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4148.1","spread":"3726.9"},{"groupId":"OG001","value":"5430.1","spread":"9067.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4105.6","spread":"3456.5"},{"groupId":"OG001","value":"6377.0","spread":"10930.6"}]}]}]},{"type":"SECONDARY","title":"Insulin Antibodies (Insulin Degludec Specific, Insulin Detemir Specific, Insulin Aspart Specific and Antibodies Cross-reacting to Human Insulin)","description":"Antibody measurements : the values presented are week 52 (LOCF). The measurement of insulin antibodies after 26 and 52 weeks of treatment was done to fulfil the requirement of monitoring the long term immunogenicity. The unit of measure is percentage bound/total (%B/T) for these antibodies. The Antibodies cross reacting to Human Insulin is abbreviated as X-reacting AB Hu Insulin below)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.6"},{"groupId":"OG001","value":"1.5","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"6.1","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.3"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":"7.7"},{"groupId":"OG001","value":"26.0","spread":"19.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":174},"commonTop":["Nasopharyngitis","Headache","Blood ketone body increased","Oropharyngeal pain","Cough"]}}}